Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Steven Hyman Insider Profile
4 Followers
Steven Hyman, Director at Voyager Therapeutics, holds ― shares in Voyager Therapeutics (Ticker: VYGR), holds 20.00K shares in Cyclerion Therapeutics (Ticker: CYCN). Most recently, Steven Hyman ― shares of Voyager Therapeutics on ― for an estimated value of ―.
Steven Hyman has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Steven Hyman holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Steven Hyman
Steven Hyman's Trading History
Voyager Therapeutics
―
Director
―
―
Cyclerion Therapeutics
Dec 04, 2023
Director
Uninformative Buy
―
$59.10K
List of latest transactions for each holding click on a transaction to see Steven Hyman's performance on stock
You May Also Like
Steven Hyman insider profile FAQ
What is the percentage of profitable transactions made by Steven Hyman?
The percentage of profitable transactions made by Steven Hyman is ―.
What is the average return per transaction made by Steven Hyman?
The average return per transaction made by Steven Hyman is ―.
What stocks does Steven Hyman hold?
Steven Hyman holds: VYGR, CYCN stocks.
What was Steven Hyman’s latest transaction?
Steven Hyman latest transaction was an Uninformative Buy of ―.
What was Steven Hyman's most profitable transaction?
Steven Hyman’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Steven Hyman's role in Voyager Therapeutics?
Steven Hyman's role in Voyager Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.